Mycobacterium phlei cell wall-nucleic acid complex in the treatment of nonmuscle invasive bladder cancer unresponsive to bacillus Calmette-Guerin

References

• Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
   Google Scholar
• Siegel R, Miller K, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.
   PubMed Web of Science ®Google Scholar
• Cancer Research UK. 2011. Available from: www.cancerresearch.org/cancer-info/cancerstats accessed 24 July 2015.
   Google Scholar
• Batteman MF, Pashos CL, Redaelli A, et al. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003;21:1315–1330.
   PubMed Web of Science ®Google Scholar
• Brausi MA. Challenging the EAU guidelines on non-muscle-invasive bladder cancer (NMIBC): single instillation of chemotherapy after transurethral resection of NMIBC and chemotherapy versus bacillus Calmette-Guérin in the treatment of intermediate risk tumors. Eur Urol. 2010;Suppl.9:406–410. doi:10.1016/j.eursup.2010.02.002
   Web of Science ®Google Scholar
• Morales ED, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116:180–183.
   PubMed Web of Science ®Google Scholar
• Morales A. Treatment of carcinoma in situ of the bladder with BCG. A phase II trial. Cancer Immunol Immunother. 1980;9:69–72.
   Web of Science ®Google Scholar
• Lamm DL, Thor DE, Harris SC, et al. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol. 1980;124:38–40.
   PubMed Web of Science ®Google Scholar
• Pinsky CM, Camacho FJ, Kerr D, et al. Intravesical administration of bacillus Calmette-Guerin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective randomized trial. Cancer Treat Rep. 1985;69:47–53.
   PubMedGoogle Scholar
• Herr HW. Extravesical tumor relapse in patients with superficial bladder tumors. J Clin Oncol. 1998;16:1099–1102.
   PubMed Web of Science ®Google Scholar
• Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized South West Oncology group study. J Urol. 2000;163:1124–1129.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168:1964–1970.
   PubMed Web of Science ®Google Scholar
• Witjes JA. Management of BCG failures in superficial bladder cancer: a review. Eur Urol. 2006;49:790–797.
   PubMed Web of Science ®Google Scholar
• Yates DR, Brausi MA, Catto JW, et al. Treatment options available for bacillus Calmette-Guerin failure in non-muscle invasive bladder cancer. Eur Urol. 2012;62:1088–96.
   PubMed Web of Science ®Google Scholar

•• A comprehensive review of options for patients not responding to bacillus Calmette–Guerin.

• Ahn JJ, McKiernan JM. New agents for bacillus Calmette-Guerin-refractory bladder cancer. Urol Clin N Am. 2013;40:219–232.
   PubMed Web of Science ®Google Scholar
• Gontero P, Bohle A, Malmstrom PU, et al. The role of bacillus Calmette-Guerin in the treatment of non-muscle invasive bladder cancer. Eur Urol. 2010;57:410–429.
   PubMed Web of Science ®Google Scholar
• Ribi EE, Milner KC, Granger DL, et al. Immunotherapy with non-viable microbacterial components. J Nat Cancer Inst. 1976;277:228–238.
   Google Scholar
• Gray GR, Ribi E, Granger D, et al Immunotherapy of cancer: tumor suppression and regression by cell walls of Mycobacterium phlei attached to oil droplets. J Nat Cancer Inst. 1975;55:727–30 Describes the pioneering work from the stone-age of cancer immunotherapy.
   PubMedGoogle Scholar
• Filion MC, Phillips NC. Therapeutic potential of mycobacterial cell wall-DNA complexes. Expert Opin Investig Drugs. 2001;10:2157–2165.
   PubMed Web of Science ®Google Scholar
• Morales A, Nickel JC, Downey J, et al. Immunotherapy of an experimental adenocarcinoma of the prostate. J Urol. 1995;153:1706–1710.
   PubMed Web of Science ®Google Scholar
• Chin JL, Kadhim SA, Batislam E, et al. Mycobacterium cell wall: an alternative to intravesical BCG therapy in orthotopic murine bladder cancer. J Urol. 1996;156:1189–1193.
   PubMed Web of Science ®Google Scholar
• Clark-Curtiss JE. Genome structure of mycobacteria. McFadde JE. London: Academic Press; 1990. p. 77–96.
   Google Scholar
• Shivannar CT, Katoch VM, Sharma VD, et al. Determination of mycobacterial phylogeny on the bases of immunological relatedness of superoxide dismutase. Int J Syst Bacteriol. 1996;46:1164–1169.
   PubMedGoogle Scholar
• Rastogi N, Legarnd E, Sola C. The mycobacteria: an introduction to nomenclature and pathogenesis. Rev Sci Tech. 2001;20:21–54.
   PubMed Web of Science ®Google Scholar
• Morales A, Chin JL, Ramsey EW. Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder. J Urol. 2001;166:1633–1638.
   PubMed Web of Science ®Google Scholar
• Filion MC, Lepecier P, Morales A, et al. Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells. Brit J Cancer. 1999;79:229–235.
   PubMed Web of Science ®Google Scholar
• Filion MC, Filion B, Reader S, et al. Modulation of interleukin-12 synthesis by DNA lacking the CpG motif and present in mycobacterial cell wall complex. Cancer Immunol Immunother. 2000;49:325–334.
   PubMed Web of Science ®Google Scholar
• Reader S, Menard B, Filion B, et al. Pro-apoptotic and immunomodulatory activity of a mycobacterial cell wall-DNA complex towards LNCaP prostate cancer cells. The Prostate. 2001;49:155–165.
   PubMed Web of Science ®Google Scholar
• Zlotta AR, Van Vooren J-P, Denis O, et al. What are the immunologically active components of bacilli Calmette-Guerin in therapy of superficial bladder cancer? Int J Cancer. 2000;87:844–852.
   PubMed Web of Science ®Google Scholar
• Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol. 2003;169:1706–1708.
   PubMed Web of Science ®Google Scholar
• Morales A, Phadke K, Steinhoff G. Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed. J Urol. 2009;181:1040–1045.
   PubMed Web of Science ®Google Scholar
• Morales A, Herr H, Steinberg G, et al. Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guerin. J Urol. 2015;193:1135–43.
   PubMed Web of Science ®Google Scholar

• The largest study published with the new modality.

• Sylvester RJ, van der Meijden AP, Witjes JA. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol. 2005;174:86- 91.
   PubMed Web of Science ®Google Scholar

•• An excellent review of the available treatments.

• Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003;169:90–95.
   PubMed Web of Science ®Google Scholar
• Weiss BE, Pietzak EJ, Wein AJ, et al. Single instillation of mitomycin C plus bacillus Calmette-Guerin (BCG) versus BCG alone in high grade non-muscle invasive bladder cancer. Can J Urol. 2015;22:7876–7881.
   PubMed Web of Science ®Google Scholar
• Dalbagni G, Russo P, Sheinfeld J, et al. Phase I trial of intravesical gemcitabine in bacillus Calmette–Guerin refractory transitional-cell carcinoma of the bladder. J Clin Oncol. 2002;20(15):3193–3198.
   PubMed Web of Science ®Google Scholar
• Addeo R, Caraglia M, Bellini S, et al. Randomized phase III trial on gemcitabine versus mitomycin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol. 2010;28:543–548.
   PubMed Web of Science ®Google Scholar
• Skinner EC, Goldman B, Sakr WA, et al. SWOGSO353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guerin. J Urol. 2013;190:1200–1204.
   PubMed Web of Science ®Google Scholar
• Shelley MD, Jones G, Cleves A, et al. Intravesical gemcitabine therapy for nonmuscle invasive bladder cancer (NMIBC): a systematic review. B J U Int. 2012;109:496–505.
   PubMed Web of Science ®Google Scholar
• Steinberg G, Bahnson R, Brosman S, et al. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. J Urol. 2000;163:761–767.
   PubMed Web of Science ®Google Scholar
• Morales A, Jablonski D, Lihou C, et al. Safety of mycobacterial cell-wall DNA complex given immediately post-surgery in patients with non-muscle invasive bladder cancer. J Urol 2012. 187(Suppl.4):e719–e720.
   Web of Science ®Google Scholar
• Quek ML, Stein JP, Daneshmand S, et al. A critical analysis of perioperative mortality from radical cystectomy. J Urol. 2006;175:886–889.
   PubMed Web of Science ®Google Scholar
• Rosario DJ, Becker M, Anderson JB. The changing pattern or mortality and morbidity from radical cystectomy. BJU Int. 2000;85:427–30.
   PubMed Web of Science ®Google Scholar

A paper showing the impact of radical cystectomy despite the continuing improvements in techniques as well as in peri- and intraoperative care.

• O’Donell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-a 2B plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol. 2001;166:1300–1305.
   PubMed Web of Science ®Google Scholar
• Punnen SJ, Chin JL, Jewett MSA. Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and interferon combination therapy. Canad J Urol. 2003;10:1790–1795.
   PubMedGoogle Scholar
• Gallagher BL, Joudi FN, Maymi JL, et al. Impact of previous bacilli Calmette-Guerin failure pattern in subsequent response to bacilli Calmette-Guerin plus interferon intravesical therapy. Urology. 2008;71:297–301.
   PubMed Web of Science ®Google Scholar
• Bazarbashi S, Soudy H, Abdelsalam M, et al. Co-administration of intravesical bacillus Calmette-Guerin and interferon α-2B as first line in treating superficial transitional cell carcinoma of the urinary bladder. BJU Int. 2011;108:1115–1118.
   PubMed Web of Science ®Google Scholar
• O’Regan T, Taton M, Lyon M, et al. The effectiveness of BCG and interferon against non-muscle invasive bladder cancer: a New Zealand perspective. BJUI. 2015;116(suppl. 3):54–60. doi:10.1111/bju.13211.
   Google Scholar
• Di Stassi SM, Giannantoni A, Stephen RL, et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol. 2003;170(3):770–782.
   Web of Science ®Google Scholar
• Bachir BG, Dragomir A, Aprokian AG, et al. Contemporary cost-effective analysis comparing sequential bacillus Calmette-Guerin and electromotive mitomycin versus bacillus Calmette-Guerin alone for patients with high risk non-muscle invasive bladder cancer. Cancer. 2014;120:2424–2431.
   PubMed Web of Science ®Google Scholar
• Nativ O, Wijes JA, Hendriksen K, et al. Combined thermos-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol. 2009;182:1313–1317.
   PubMed Web of Science ®Google Scholar
• Lammers RJ, Witjes JA, Inmab BA, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle invasive bladder cancer: a systematic review. Eur Urol. 2011;60:81–86.
   PubMed Web of Science ®Google Scholar
• Geijsen ED, de Reijke TM, Koning CC, et al. Combining mitomycin C and regional 70 MHz hyperthermia in patients with nonmuscle invasive bladder cancer: a pilot study. J Urol. 2015;194:1202–1208.
   PubMed Web of Science ®Google Scholar
• Barlow LJ, McKiernan JM, Benson MC. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guerin therapy. J Urol. 2013;189(3):834–839.
   PubMed Web of Science ®Google Scholar
• McKiernan JM, Barlow LJ, Laudano MA, et al. A phase I trial of intravesical nonparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guerin refractory nonmuscle invasive bladder cancer. J Urol. 2011;186:448–451.
   PubMed Web of Science ®Google Scholar
• Olsson CA, Chute R, Rao CN. Immunological reduction of bladder cancer recurrence rate. J Urol. 1974;111:173–176.
   PubMed Web of Science ®Google Scholar
• Lammers RJM, Witjes WPJ, Janzing-Pastors MHD, et al. Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle invasive bladder cancer: results from a prospective randomized phase III trial. J Clin Oncol. 2012;30:2273–2279.
   PubMed Web of Science ®Google Scholar
• Burke JM, Lamm D, Meng MV, et al. A first in human phase 1 study of CG0070, a CMG-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol. 2012;188:2391–2397.
   PubMed Web of Science ®Google Scholar
• Kowalski M, Guindon J, Brazas L, et al. A phase II study of oportozumab monatox: an immunotoxin therapy for patients with non-invasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guerin. J Urol. 2012;188:1712–1718.
   PubMed Web of Science ®Google Scholar
• Dinney CPN, Fisher MB, Nevai N, et al. Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for bacillus Calmette-Guerin failures in nonmuscle invasive bladder cancer. J Urol. 2013;190:850–856.
   PubMed Web of Science ®Google Scholar
• Surolia I, Gulley J, Madan RA. Recent advances in the use of therapeutic vaccines in genitourinary malignancies. Expert Opin Biol Ther. 2015;14:1769–1781.
   Web of Science ®Google Scholar
• Dobrovolskaia MA, McNeil SE. Immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics. Expert Op Biol Ther. 2015;15:1023–1048.
   PubMed Web of Science ®Google Scholar

•• A superb review of the promise and challenges of this technology.

• Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2020. J Nat Cancer Inst. 2011;103:117–28.
   PubMed Web of Science ®Google Scholar

• An eye opener on the cost of dealing with bladder cancer.